SION Files Form 8-K Furnishing Q2 2025 Financial Results as Exhibit 99.1

Rhea-AI Filing Summary

Sionna Therapeutics furnished a press release announcing its financial results and business highlights for the quarter ended June 30, 2025. The Form 8-K states the full text of that press release is furnished as Exhibit 99.1 to the Current Report and clarifies that the information is furnished, not filed, so it is not subject to Section 18 liabilities or incorporated by reference in other filings unless expressly stated. The filing also confirms the company’s Delaware incorporation and Nasdaq listing under the ticker SION, and indicates the company qualifies as an emerging growth company. Investors should consult Exhibit 99.1 for the actual financial figures and business highlights.

Insights

Financial Analyst

TL;DR: Routine quarterly press release furnished; this 8-K contains no financial figures—review Exhibit 99.1 for results.

The Form 8-K notifies the market that a press release with quarterly results and business highlights has been furnished as Exhibit 99.1. As presented, the filing itself does not disclose revenues, earnings, or quantitative metrics, so it provides a procedural disclosure rather than new financial detail. Because the disclosure is furnished (not filed), it carries the narrower liability treatment the company states. Material investor implications depend entirely on the contents of Exhibit 99.1.

Corporate Governance Expert

TL;DR: Procedural disclosure; furnishing the press release limits Section 18 exposure and does not incorporate the release by reference.

The filing emphasizes the company has furnished rather than filed the press release, which is a common governance practice to share timely results while limiting certain liabilities. The 8-K confirms the presence of Exhibit 99.1 as the vehicle for substantive information. From a governance standpoint, the company has followed standard disclosure protocol; however, the Form 8-K itself does not allow assessment of financial or operational performance without consulting the exhibit.

0002036042FALSE00020360422025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________

FORM 8-K

__________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 11, 2025

__________________________

SIONNA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

__________________________

Delaware			001-42504			84-2801521
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

SIONNA THERAPEUTICS, INC.

21 Hickory Drive, Suite 500

Waltham, MA02451

(Address of principal executive offices, including zip code)

617-819-2020

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

SION

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On August 11, 2025, Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

99.1			Press Release of Sionna Therapeutics, Inc. dated August 11, 2025.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Sionna Therapeutics, Inc.
Date: August 11, 2025			By:			/s/ Jennifer Fitzpatrick
			Name:			Jennifer Fitzpatrick
			Title:			Chief Legal Officer

FAQ

What did Sionna Therapeutics (SION) report in this Form 8-K?

The Form 8-K states Sionna furnished a press release announcing financial results and business highlights for the quarter ended June 30, 2025, furnished as Exhibit 99.1.

Does this 8-K include the company’s financial figures?

No. The 8-K indicates the press release containing results is furnished as Exhibit 99.1; the filing body does not present specific financial numbers.

Is the press release considered filed or furnished under the Exchange Act?

The company explicitly states the press release is furnished, not filed, so it is not subject to Section 18 liabilities or automatically incorporated by reference in other filings unless expressly done so.

Where is Sionna Therapeutics listed and what is its ticker?

The filing shows Sionna’s common stock is listed on the Nasdaq Global Market under the ticker SION.

Is Sionna identified as an emerging growth company in this filing?

Yes. The Form 8-K indicates the registrant has checked the box confirming it is an emerging growth company.